- Company
- Kolon Life Science faces 88.5-billion-won damage lawsuits
- by Kim, Jin-Gu Nov 18, 2019 10:21pm
- Kolon Life Science is facing a series of damage lawsuits asking for 88.5 billion won as compensation for the Invossa incident. Kolon Life Science stated in the third quarter report that the company’s properties have been seized by Mitsubishi Tanabe and outstanding contract payment from Mundipharma has been suspended. It is facing number of
- Policy
- 5 or more medications were taken by 68% for older people
- by Kim, Jung-Ju Nov 18, 2019 05:34pm
- Korean proportion of 75 years and over who are taking more than 5 medications concurrently exceeded 68%. It is far exceeding the average of 48% of OECD &8211;member countries. Diabetic prescription rate of first choice antihypertensive medication patientsis 78%, which is lower than the average of 83% in OECD-member countries, but is steadily
- Company
- AI-driven Drug Discovery is already signigicantly high level
- by Kim, Jin-Gu Nov 18, 2019 04:47pm
- Global pharmaceutical companies are showing great interest in the development of new drugs using artificial intelligence (AI). It is expected that AI will drastically reduce the time and costs associated with finding a candidate substance through clinical trials and approvals before entering the market. What about the perspective of the
- Policy
- VMS treating fezolinetant Phase 3 approved in Korea
- by Lee, Tak-Sun Nov 18, 2019 06:23am
- An investigational medicine treating vasomotor symptoms (VMS) associated with menopause is to conduct a Phase 3 clinical trial in Korea. On Nov. 15, Ministry of Food and Drug Safe approved of Investigational New Drug (IND) application of fezolinetant for transnational Phase 3 clinical trial taking place in Korea. Acquired by a Japanes
- Company
- Pfizer’s Upjohn changed in business name to Viatris
- by Eo, Yun-Ho Nov 18, 2019 06:23am
- Pfizer's Upjohn is expected to be reborn as a complete independent corporation, or one pharmaceutical company, next year. According to the relevant industry, Pfizer and Mylan decided to change the name of the company to Viatris in 2020 after the merger of the patent expiry division. This means complete company separation. Currently,
- Company
- Average 300 days required for new drug approval in Korea
- by Eo, Yun-Ho Nov 18, 2019 02:00am
- It is confirmed that an average of 300 days is spent before a new drug is approved in Korea. The Korean Research-based Pharmaceutical Industry Association (KRPIA), in the 'Study on the New Drug License Period in Korea', disclosed that 115 new drug items approved in Korea took an average of about 300 days for the approval and the review p
- Policy
- Pharmaceutical industry, submit α-GPC data MFDA, scrutiny
- by Lee, Tak-Sun Nov 18, 2019 01:47am
- The pharmaceutical industry has submitted a full range of data to the MFDA to validate the choline alfoscerate formulations. In addition to supporting evidence from L'iniformatore Farmaceutico (Italy), it is reported to include all the supporting evidence, such as interim research of Ascomalva, which studied the combined effects of Done
- Company
- Combination therapy dominates in DPP-4 inhibitor market
- by Chon, Seung-Hyun Nov 17, 2019 05:35pm
- While dipeptidyl peptidase-4 (DPP-4) inhibitor products are currently leading the Korean oral diabetic treatment market, combination drugs reaffirmed its dominance over the DPP-4 market taking up two-thirds of the pie. Even compared with monotherapy prescription volume, MSD’s combination drug with DDP-4 inhibitor and metformin, Janumet outdid o
- Company
- Prosecution combs vaccine companies for alleged collusion
- by Kim, Jin-Gu Nov 16, 2019 06:29am
- The prosecution set out to investigate on a suspicion of pharmaceutical companies colluding together when supplying vaccine to government. According to pharmaceutical industry on Nov. 14, the prosecution combed ten alleged pharmaceutical companies and distributors on Nov. 13. Companies like GC Pharma, Kwangdong Pharmaceutical, Boryung Ph
- Company
- Novatis Korea, 5 Copyright arrangements including Exelon
- by An, Kyung-Jin Nov 16, 2019 06:28am
- Novartis Korea is working copyright control of some central nervous system (CNS) medicines such as Excelon. According to the industry on 14th Novartis Korea is considering selling the copyrights of some of the CNS products sold by the Rx medicine business division. The intention is to clean up less profitable items and focus sales mark
